DDInter1266 DDInter210
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Naproxen {u} (Compound) causes {v} (Side Effect) Paralysis
Paralysis {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Naproxen {u} (Compound) causes {v} (Side Effect) Skin exfoliation
Skin exfoliation {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Naproxen {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) is upregulated by {v} (Compound) Albendazole
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Naproxen (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Naproxen (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Naproxen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Naproxen (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Naproxen (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) is upregulated by Albendazole (Compound) and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Naproxen (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Binimetinib
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Binimetinib
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib